A double-blind placebo-controlled study of VP4896 for the treatment of mild-to-moderate Alzheimer's disease

Trial Profile

A double-blind placebo-controlled study of VP4896 for the treatment of mild-to-moderate Alzheimer's disease

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Curaxis Pharmaceutical Corporation
  • Most Recent Events

    • 16 Aug 2006 Status change
    • 14 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top